Alzheimer's Disease - Amyloid Beta- Directed Antibodies - Kisunla
Customize your policy alerts
Sign up for Cigna Policy IP0697 alerts
Get alerted when Policy IP0697 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical necessity, coding, and coverage criteria for Kisunla (donanemab-azbt) intravenous infusion for treatment of Alzheimer's disease for Cigna members. It affects providers seeking authorization and reimbursement for Kisunla.
Policy name updated from 'Neurology - Kisunla' to 'Alzheimer's Disease - Amyloid Beta- Directed Antibodies - Kisunla.'
Experimental, investigational or unproven statement updated to include 'regardless of U.S. Food and Drug Administration (FDA) approval status. Criteria will be updated as new published data are available.'
Documentation statement was added to the policy.
Alzheimer's Disease condition of approval was added; prior 'Conditions Not Covered: Alzheimer's' was removed.
Coverage Criteria for Kisunla (donanemab-azbt)
Medical Necessity Statement
Considered medically necessary when the criteria in the applicable policy statements are met:
See related policy statements for detailed clinical eligibility criteria and documentation requirements.
Kisunla (donanemab-azbt) is considered medically necessary when the criteria in the applicable policy statements are met. For purposes of billing and prior authorization, the HCPCS code associated with Kisunla is J0175 (Injection, donanemab-azbt, 2 mg) and prior authorization is required when the clinical criteria are satisfied.
Conditions Not Covered have been revised. Notably, the prior exclusion listing 'Alzheimer's' under Conditions Not Covered was removed as part of recent policy updates; the policy's revision history documents the addition of an Alzheimer's disease condition of approval and removal of Alzheimer's from the Conditions Not Covered list. Providers should refer to the revision history for effective dates of these changes.
Coding and Billing
| J0175 | Injection, donanemab-azbt, 2 mg |
Provider Actions and Requirements
Billing rule: confirm HCPCS code eligibility at time of service
Verify use and coding at the time of service and include HCPCS J0175 on claims; deleted or noneffective codes at the time of service may not be eligible for reimbursement.
- Confirm code eligibility at time of service per policy note about code lists and deleted/noneffective codes.
Documentation must be submitted with authorization requests
Include the documentation required by the policy when requesting authorization; a documentation statement was added to the policy and must be supplied with coverage requests.
- Provide any clinical documentation specified in the policy at time of prior authorization request.
Off‑label use denial risk — noncovered uses
Kisunla used for any indication other than those meeting the policy's specified criteria is considered not medically necessary and may be denied.
- Policy states off-label or other uses are not medically necessary; criteria will be updated as new published data are available.
Background
Donanemab (marketed as Kisunla) is an amyloid beta‑directed monoclonal antibody administered by intravenous infusion for the treatment of Alzheimer's disease. The policy notes that clinical criteria will be updated as new published data become available and that documentation requirements were added to support authorization requests.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.